Upload
madurai
View
532
Download
0
Tags:
Embed Size (px)
Citation preview
PLATINUM COMPOUNDS
9/10/2012
DR. R. RAJKUMAR III YR POST GRADUATE DEPARTMENT OF MEDICAL ONCOLOGY
Derivati del platino
Get big cell kill from fluorouracil, be a medicine man with melphalan, keep things pristine with vincristine, shout with glee with 6MP… but, and this is important for today, you can flatten ’em, with platinum
Sir Kenneth was Chief Medical Officer for Scotland and for England, and is now the Vice-Chancellor of the University of Durham
Witness Seminar held by the Wellcome Trust Centrefor the History of Medicine at UCL, London, on 4 April 2006
The compound cis-PtCl2(NH3)2 was first described by M. Peyrone in 1845, and known for a long time as Peyrone's salt.
The structure was deduced by Alfred Werner in 1893.
In 1965, Barnett Rosenberg, van Camp et al. of Michigan State University discovered that electrolysis of platinum electrodes generated a soluble platinum complex which inhibited binary fission in Escherichia coli (E. coli) bacteria. Although bacterial cell growth continued, cell division was arrested, the bacteria growing as filaments up to 300 times their normal length. Cisplatin was approved for use in testicular and ovarian cancers by the U.S. Food and Drug Administration on December 19, 1978.
History of Cisplatin
Barnett Rosenberg(1961)
• To study the effect of electric fields on Cell Division (like Mitosis)
• Started with Escherichia coli bacterial cells
Idea !
V
Anodo di Pt
catodo di Pt
batteri medium
L’esperimento di Rosenberg
THE PLATINUMS
PROPRIETÀ CHIMICHE CHE GOVERNANO L’ATTIVITÀ CLINICA DEI COMPLESSI DEL PLATINO
1. Configurazione2. Stato di ossidazione
leaving groups
3.Natura dei gruppi uscenti (leaving groups)
carrier ligands
4. Natura dei carrier ligands
reattivo nella cellua
Chimica del cisplatino in soluzione acquosa
NH3
PtH3N OH2
Cl
NH3
PtH3N Cl
Cl
NH3
PtH3N OH2
OH2
NH3
PtH3N OH2
Cl
G
G+
major groove
NH3
PtH3N
Cl
G
G
major groove
H3NPt
H3N
G
G
major groove
Addotti del cisplatino con il DNA
Cisplatin coordinates to DNA and that this coordination complex not only inhibits replication and transcription of DNA, but also leads to programmed cell death (called apoptosis)
Action of Cisplatin
Cisplatin in cell level
Binding site in Base Pairs…
Geometrical Isomer
• In vitro studies on both prokaryotic and eukaryotic cells revealed that DNA adducts of both cisplatin and trans-DDP blocked the action of DNA polymerase
• In vivo studies showed that cisplatin and trans-DDP inhibited replication equally well
• DNA replication is not the only factor important for the clinical activity of cisplatin
The cytotoxic activity of cisplatin may arise from the cell’s inability to repair DNA damage caused by cisplatin.
• The cell detects DNA damage by the action of damage recognition proteins
• HMG-domain proteins bind cisplatin–DNA adducts in vitro
• In vivo assays on yeast shown that HMG-domain proteins are important for the activity of cisplatin:
• These effects may also be in operation in mammalian cells
1. HMG domain containing transcription factors bind preferentially to the cisplatin–DNA adducts, they could wreak havoc with the transcriptional machinery
2. When HMG domain proteins bind to the cisplatin–DNA adducts, the adducts would not be recognized by the repair machinery
Role of HMG domain proteins
DNA-Cisplatin-HMG adduct
INDICATIONS
• NSCLC• SCLC• AERODIGESTIVE TRACT
MALIGNANCIES• LOWER G.I. MALIGNANCIES• GYNECOLOGIC MALIGNANCIES• GENITOURINARY MALIGNANCIES• HEAD&NECK CANCERS
Cisplatin Administration• Mixed in 250 - 1000 ml NS • Mixed with 2 – 4 grams magnesium sulfate in
same bag• Infused over atleast 2 hours• Pre-hydration of 250 – 1000 mL NS depending
on dose – ensure adequate UOP (> 200 cc/2 hours) – Caution in patients with HF or CRI who
cannot tolerate this amount of fluids– May require furosemide IVP
• Post-hydration with 1 Liter NS – instruct patient to drink 6 – 8 full glasses of
water/day (1.5 – 2 Liters/day) at home
CISPLATIN TOXICITY
• Nausea and vomiting– acute or delayed– highly emetogenic if use doses than 50 mg/m2
– moderately emetogenic if use doses 50 mg/m2– severe if not adequately prevented with appropriate
medications– typical anti-emetic regimen
• aprepitant 125 mg po day 1 then 80 mg po days 2 – 3• dexamethasone 12 mg po day 1 then 8 mg po daily x 3
days• palonosetron 0.25 mg IVP day 1• metoclopramide 10 mg every 4 hours prn N/V
CISPLATIN TOXICITY
• HEMATOLOGIC TOXICITY– can affect all 3 blood lineages– minor neutropenia, thrombocytopenia, and ANEMIA– its mild hematologic toxicity has allowed its
combination with highly myelosuppressive chemotherapy
• OTOTOXICITY– audiograms show bilateral and symmetrical high
frequency hearing loss– usually irreversible– caution with other drugs (aminoglycosides)
CDDP-INDUCED ORGAN TOXICITY
* Nephrotoxicity
* Neurotoxicity
* Cardiomyopathy
CDDP CARDIOMYOPATHY
1- Electrocardiographic changes
2- Myocarditis
3- Arrythmia
4- Congestive heart failure
5- Bradycardia
6- Lethal cardiomyopathy when CDDP
is given in combination chemotherapy protocols containing MTX, 5-FU, BLM, and DOX
CISPLATIN TOXICITY
• Neurotoxicity– dose-limiting toxicity– most common symptoms are peripheral neuropathy and
hearing loss– less common include Lhermitte’s sign (electric shock-like
sensation transmitted down the spine upon neck flexion)– autonomic neuropathy, seizures, encephalitic symptoms, and
vestibular disturbances– cumulative doses > 300 mg/m2– first signs are loss of vibration sensation, loss of ankle jerks
and painful paresthesias in hands and feet– proximal progression and deficits in proprioception, light touch
and pain– recovery is typically incomplete
CISPLATIN TOXICITY
• Nephrotoxicity– dose-limiting toxicity– renal damage is usually reversible but rarely can be
irreversible and require dialysis– platinum concentrations are higher in the kidney than in the
plasma or other tissues– initiating event is proximal tubular lesion– secondary events such as disturbances in distal tubular
reabsorption, renal vascular resistance, renal blood flow, and glomerular filtration, and polyuria seen 2 to 3 days later
– hypomagnesemia develops in about 75% of patients, beginning 3 to 12 weeks after therapy and persisting for months to years
CISPLATIN NEPHROTOXICITY
CISPLATIN NEPHROTOXICITY
CISPLATIN NEPHROTOXICITY
• Preventive Measures– aggressive saline hydration (enhance urinary
excretion)– lower doses may require less hydration– infuse over 24 hours– pretreatment with amifostine– avoid other nephrotoxic agents– magnesium supplementation– predisposing factors to developing nephrotoxicity
include age 60 years or older, higher doses, pretreatment GFR < 75 ml/min, cumulative dose, low albumin, single dose compared with daily x 5 administration schedules
57
Drug Interactions DRUG INTERACTIONS
• Phenytoin ... decreased epilepsy control• Frusomide, hydralazine, diazoxide &propranolol increased nephrotoxicity• Dose adjustment of Allopurinol & colchicine
doses needed due to hyperuricemia of Cisplatin • Antihistamines mask ototoxicity of cisplatin• Cephalosporins Abs e.g. Cephalexin & Aminoglycosides Abs e.g. Gentamycin increased nephrotoxicity• Live attenuated vaccines are contraindicated
CISPLATIN RESISTANCE
Putative Mechanisms of Cisplatin Resistance
1
2
3
4
5
6
Kartalou, 2001
CARBOPLATIN
CLINICAL PHARMACOLOGY OF CARBOPLATIN•Both carboplatin and cisplatin exert their therapeutic effects primarily by forming intrastrand DNA adducts with adjacent guanine residues in tumor-cell DNA .• Although the platinum-containing moieties of carboplatin and cisplatin are identical , it is the unique leaving groups of each that ultimately facilitate DNA binding.• In the case of carboplatin,the carboxylate groups are much more stable adducts than the chloride groups of cisplatin. This decreases the chemical reactivity of carboplatin relative to cisplatin and significantly lengthens the time required for its aquation and subsequent DNA-adduct formation .
CARBOPLATIN
• IV NORMAL SALINE.• DOSING-mg/m2×min(AUC).• DOSE-4,5,or6mg/m2×min,in 250ml NS,
3-4 weeks.• INFUSION TIME- 1hr-4hr.• LESS NEPHROTOXIC, MORE
MYELOTOXIC
•Carboplatin is excreted almost exclusively by the kidneys.
•The total body clearances of ultrafiltrable platinum and that of the parent carboplatin molecule are roughly equivalent and correlate linearly with the pretreatment glomerular filtration rate (GFR).
•Approximately 65%-70% of the total platinum dose is eliminated as intact carboplatin in the urine during the first 12-16 hours after administration, while theremaining 30%-35% of the dose, which is protein-bound and inactive, is eliminated slowly over the next five days
CALVERT’ S FORMULA
Total dose (mg) = target AUC (mg/ml ´ min)´ (GFR [ml/min] + 25)
The value of 25 ml/min is a constant that used to correct for the nonrenal clearance of irreversibly tissue-bound carboplatin .
CARBOPLATIN TOXICITY • Moderately emetogenic • Renal impairment is rare
– because it is excreted primarily in the kidneys as an unchanged drug, it is not directly toxic to the renal tubules
• Neurotoxicity is rare• Myelosuppression
– especially THROMBOCYTOPENIA– dose-limiting toxicity– cumulative
• Hypersensitivity reaction– thought to be due to type I hypersensitivity (IgE mediated)– incidence of hypersensitivity seems to be correlated with
increased number of cycles of carboplatin administered– risk of hypersensitivity due to carboplatin exposure
significantly increases during the sixth cycle, and it continues to increase up to cycle 8
OXALIPLATIN
•Oxaliplatin differs from cisplatin in that the amine groups of cisplatin are replaced by diaminocyclohexane (DACH). • The molecular weight of oxaliplatin is 397.3. • It is slightly soluble in water, less so in methanol, and almost insoluble in ethanol and acetone .• Its full chemical name, oxalato(trans L- 1,2 diaminocyclohexane)platinum, refers to the presence of an oxalate “leaving group” and the DACH carrier ligand, which are responsible, at least in part, for its unique properties
OXALIPLATIN
• IV IN 5%DEXTROSE.DOSING IN mg/m2• DOSE-85-130mg/m2 ,2-3weeks• INFUSION TIME-6hr, but 2hr and 4 hr is
used.• COLORECTAL CANCER
Oxaliplatin Toxicity• Gastrointestinal
– Moderate emetogenicity– diarrhea
• Minimal hematologic toxicity– Thrombocytopenia is dose-related (doses > 135 mg/m2)– mild neutropenia– mild anemia
• No nephrotoxicity• Hypersensitivity reaction
– mild– generally subside upon discontinuation– slowing down infusion rate and giving an antihistamine and/or
steroid– desensitization protocol
• Peripheral neuropathy– Prevention: Stop and Go Strategy, Ca and Mg infusions (may
compromise efficacy)
Clinical characteristics of oxaliplatin neurotoxicity
Acute symptoms Chronic symptoms
• Common (90% of patients)• May appear at first treatment cycle• Generally mild• Onset during or within hours of
infusion• Transient, short lived• Cold-triggered or cold-aggravated• Dysesthesias and paresthesias• Manifesting as stiffness of the
hands or feet, inability to release grip, and sometimes affecting the legs or causing contractions of the jaw
• Distal extremeties, perioral, oral, and pharyngolaryngeal areas
• Depending on dosing schedule (infusion rate)
• 10% to 15% moderate neuropathy after a cumulative dose of 780 to 850 mg/m2
• Does not seem to be schedule-dependent
• Dysesthesias and paresthesias persisting between cycles
• Progressively evolving to functional impairment: difficulties in activities requiring fine sensorimotor coordination, sensory ataxia
• Tends to improve/recover after treatment is stopped
• Spares motor neurons (like cisplatin)
OXALIPLATIN NEUROPATHY
Supportive care for prevention of oxaliplatin induced neuropathy
avoid cold temperatures if exposure to cold temperatures cannot be
avoided, such as use of the refrigerator, wear gloves during the exposure
use scarves and face masks in cold weather prolonging the infusion time use cotton socks, pot holders, rubber gloves
for dish washing assess the water temperature in the home use moisturizer
COMPARISON OF PLATINUM TOXICITY
Table 5. Comparative adverse effect profiles of platinum drugs
Adverse effect cisplatin carboplatin oxaliplatin
Nephrotoxicity ++ + -
Gastrointestinal toxicity
+++ + +
Peripheral neurotoxicity
+++ - ++
Ototoxicity + - -
Hematologic toxicity + ++ +
Hypersensitivity - + -
DISEASE COMPARISONS OF PLATINUM ANALOGUES
• OVARIAN CANCER- CLINICAL EQUIVALENCY FOR CDDP & CARBO
• TESTICULAR CANCER- SUPERIORITY FOR CDDP
• NSCLC- CDDP MAY OFFER IMPROVED EFFICACY
• SCLC- CARBO EQUAL EFFICACY & LESS TOXIC
• COLORECTAL CANCER –OXALIPLATIN STRONGLY SUPERIOR
DISEASE COMPARISONS OF PLATINUM ANALOGUES
• CERVIX CANCER- CDDP – OPTIMAL RADIOSENSITIZER. CARBO-ACTIVE
• GASTRIC CANCER-CDDP SUPERIOR, OXALIPLATIN EQUIVALENT
• ESOPHAGEAL CANCER- CDDP OPTIMAL RADIOSENSITIZER. CARBO-ACTIVE
• HEAD&NECK CANCER- CDDP OPTIMAL RADIOSENSITIZER.CARBO ACTIVE.
SATRAPLATIN
A novel oral platinum compound Activity against cell lines resistant to taxane
and other platinum compounds
bis-(acetato)-ammine dichloro-(cyclohexylamine) platinum IV
Proposed Indication
Orplatna® (satraplatin capsules) is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer that has failed prior chemotherapy.
SATRAPLATIN
• ORALLY 5 TIMES DAILY.• DOSING –mg/m2.• DOSE- 80mg/m2/day D1-D5.• PROSTATE CANCER.
Satraplatin and Prednisone Against Refractory Cancer
SPARC Trial (n=912)
Progressive HRPC1 prior chemo
Satraplatin 80 mg/m2/d x 5 po q5wks+ Prednisone 5 mg x 2/daily Q 35 days
Placebo + Prednisone 5 mg x 2/daily Q 35 days
1° Endpoint: 30% increase in TTP with 85% power 2° Endpoints: OS, time to pain progression
2:1
RANDOMIZE
J.Bellmunt 09/2008
Progression Free Survival100
0
10
20
30
40
50
60
70
80
90
0 10 20 30 40 50 60 70 80 90
Weeks
Su
rviv
al P
rob
ab
ilit
y (
%)
Satraplatin + Prednisone
Placebo + Prednisone
HR: 0.67 (95% CI: 0.57 - 0.77)
Log-Rank P = 0.0000003
S PMedian (wks) 11.1 9.7
J.Bellmunt 09/2008
Any queries????
QUERIESVisit :www.bpharmstuf.com
THANK YOU